Australian (ASX) Stock Market Forum

HXL - Hexima Limited

Jump to new
System

System

Joined
27 June 2010
Posts
4,147
Reactions
309
Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics.

Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally.

Hexima is based in Melbourne, Australia.

It is anticipated that HXL will list on the ASX during December 2020.

Hexima Home | Hexima

Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.
hexima.com.au hexima.com.au
 
not really getting market attention. Phase IIB results released

IPO at 20c: daily
1618640637763.png
 
HXL has been in my watch list and though i haven't bought into the low traded company, I'LL take it for the 2022 yearly comp and keep an eye on it for weakness
 
charlsie said:
HXL has been in my watch list and though i haven't bought into the low traded company, I'LL take it for the 2022 yearly comp and keep an eye on it for weakness
Click to expand...
Oh no. There's weakness and then there's this... ?
What happened to cause this?

Screenshot_20221008-212646.png
 
Phase 11 trial results did not match Phase 1 potential. Did not proceed to phase 111.

Curious spike in latest price though.
 
Top